Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Heterologous

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Heterologous. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-001556-19 Sponsor Protocol Number: COL_SCU_2011 Start Date*: 2012-11-08
    Sponsor Name:FUNDACION IMABIS
    Full Title: A Prospective, Randomized, Doubled-masked, Single Center, Clinical Comparison of Autologous Serum, Heterologous Serum and Umbilical Cord Serum Eye Drops in the Management of Dry Eye Syndrome
    Medical condition: Ocular surface disturbances.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001331-10 Sponsor Protocol Number: VAC52150EBL2005 Start Date*: 2021-03-10
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV and MVA-BN®-Filo in Infants Aged 4-11 Months in Guinea and S...
    Medical condition: Ebola
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10014071 Ebola disease PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003458-42 Sponsor Protocol Number: 116938 Start Date*: 2016-06-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II observer-blind, multicentre, dose-ranging study of children 6 to less than 36 months of age who are to be primed with a 2-dose series of GSK Biologicals’ AS03-adjuvanted A/Indonesia/05/2...
    Medical condition: Healthy volunteers (Active immunization against influenza A virus H5N1 subtype).
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003666-13 Sponsor Protocol Number: VAC89220HPX3002 Start Date*: 2019-10-15
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1...
    Medical condition: Prevention of HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000063-51 Sponsor Protocol Number: mRNA-1273-P305 Start Date*: 2024-01-01
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 2/3, Randomized, Observer-blind, Active-controlled, Multicenter Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison with mRNA-1273 (Prototype) Booster ...
    Medical condition: SARS-CoV-2
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004674-94 Sponsor Protocol Number: WI237607 Start Date*: 2019-04-05
    Sponsor Name:Riga Stradiņš University
    Full Title: Open-label Phase IV Study to Investigate Broad-and Cross-neutralizing Antibodies after Primary Vaccination with Two Different TBE Vaccines
    Medical condition: Active (prophylactic) immunization against tick-borne encephalitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10043847 Tick-borne viral encephalitis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000691-42 Sponsor Protocol Number: VAC52150EBL3001 Start Date*: 2019-04-25
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola
    Medical condition: Prevention of Ebola virus disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10014071 Ebola disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016268-35 Sponsor Protocol Number: 113883 Start Date*: 2009-12-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, observer blind study to evaluate the safety and immunogenicity of three different vaccination schedules employing two formulations of the monovalent A/California/7/2009 (H1N...
    Medical condition: Immunization of healthy children aged 10 to less than 18 years against A/California/7/2009 (H1N1)v-like influenza
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002171-19 Sponsor Protocol Number: HEVACC Start Date*: 2021-05-12
    Sponsor Name:Medizinische Universität Innsbruck, Institut für Virologie
    Full Title: Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost
    Medical condition: Immunization for SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10021433 Immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001512-28 Sponsor Protocol Number: COVIM Start Date*: 2021-05-11
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Immunogenicity of COVID-19 vaccines in medical staff and special risk populations
    Medical condition: SARS-CoV-2 immunogenicity
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005053-40 Sponsor Protocol Number: V70_29 Start Date*: 2014-11-25
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l
    Full Title: A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non Adjuvanted Trivalent Influenza Vaccine ...
    Medical condition: Prevent the attack rates of influenza during both pandemic and interpandemic periods. .
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000643-27 Sponsor Protocol Number: VAC071 Start Date*: 2019-09-23
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: A Phase IIa challenge study to assess efficacy of the Plasmodium vivax malaria vaccine candidates ChAd63 PvDBP and MVA PvDBP in healthy adults living in the UK
    Medical condition: Plasmodium vivax malaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10047665 Vivax malaria (benign tertian) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-002452-40 Sponsor Protocol Number: Td500056 Start Date*: 2023-03-08
    Sponsor Name:Sanofi Pasteur
    Full Title: Immune Response to Pertussis after Vaccination with a Tdap-IPV Booster Vaccine in Children in the Republic of South Africa: Effect of Homologous and Heterologous Pertussis Vaccination Priming Backg...
    Medical condition: Bacterial infections
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    21.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005092-18 Sponsor Protocol Number: CS I-020502/01 Start Date*: 2007-01-08
    Sponsor Name:KUROS BIOSURGERY AG
    Full Title: A phase 2a, multi-centre, controlled study of the safety and efficacy of wound healing gel I-020502 in patients undergoing autologous meshed skin grafting.
    Medical condition: Deep partial-thickness and full-thickness burns require grafting procedures to achieve wound healing and closure. Autologous grafting eliminates the risk of transmissible diseases but may be compli...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10053615 Thermal burn LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001894-26 Sponsor Protocol Number: CP-PRO-QVLP-014 Start Date*: 2018-10-18
    Sponsor Name:Medicago R&D Inc.
    Full Title: A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Ad...
    Medical condition: Seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-000596-27 Sponsor Protocol Number: VAC52150EBL2001 Start Date*: 2015-05-18
    Sponsor Name:Janssen Vaccines & Prevention BV
    Full Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebol...
    Medical condition: Ebola
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10014071 Ebola disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005477-22 Sponsor Protocol Number: 107495 Start Date*: 2007-01-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H...
    Medical condition: Immunization against influenza disease during pandemic in subjects aged 18 to 60 years.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000988-14 Sponsor Protocol Number: CCD05 Start Date*: 2016-10-12
    Sponsor Name:PROMETHERA Biosciences S.A./N.V.
    Full Title: Title: Open, Prospective, Historic-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Infusion of Liver Cell Suspension (HHLivC) in Children with Urea Cycle Disorders
    Medical condition: Neonatal-onset type of the following urea cycle disorders (UCD): ornithine transcarbamylase deficiency (OTCD), carbamoylphosphate synthetase I deficiency (CPS1D), or argininosuccinate synthetas...
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004734-33 Sponsor Protocol Number: 109825 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase II, non-randomised, open-label study to evaluate the safety and immunogenicity of the adjuvanted (pre-) pandemic H5N1 influenza candidate vaccine following a heterologous prime-boost schedu...
    Medical condition: Immunisation of healthy children aged 6 to 35 months against H5N1 influenza.
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000322-21 Sponsor Protocol Number: TIP5 Start Date*: 2012-05-29
    Sponsor Name:Sanaria Inc.
    Full Title: Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis
    Medical condition: Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:07:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA